Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014–2015 influenza season in Alberta, Canada

Influenza and other Respiratory Viruses

Volumn 10, Issue 6, 2016, Pages 532-535

  Chaudhry, Ahsan ^a   Bastien, Nathalie ^b   Li, Yan ^b   Scott, Allison ^c   Pabbaraju, Kanti ^d   Stewart, Douglas ^a   Wong, Sallene ^d   Drews, Steven J ^e,f  

^a UNIVERSITY OF CALGARY   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c Surveillance and Assessment   (Canada)

^d Alberta Provincial Health Laboratory   (Canada)

^e Prov Laboratory of Northern Alberta   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

H3N2; influenza; neuraminidase inhibitors; reduced susceptibility; resistance; sequence analysis

Indexed keywords

OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CANADA; CASE REPORT; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLUENZA A (H3N2); LABORATORY TEST; MALE; MIDDLE AGED; NASOPHARYNX; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN;

EID: 84991088766     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12415     Document Type: Article

References (14)

1. World Health Organization. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses. http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/nai_overview/en/. Accessed November 11, 2015.
2. Eshaghi A, Shalhoub S, Rosenfeld P, et al. Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient. Antimicrob Agents Chemother. 2014;58:7188–7197.
3. Babady NE, Laplante JM, Tang YW, St GK. Detection of a transient R292K mutation in influenza A/H3N2 viruses shed for several weeks by an immunocompromised patient. J Clin Microbiol. 2015;53:1415–1418.
4. Plakokefalos ET, Markoulatos P, Spyrou N, Bei TA, Vamvakopoulos NC. Molecular and phylogenetic analysis of haemagglutinin and neuraminidase sequences from recent human influenza type A (H3N2) viral isolates in Southern Greece. Arch Virol. 2001;146:1899–1918.
5. Skowronski DM, Chambers C, Sabaiduc S, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20:1–18.
6. Skowronski DM, Janjua NZ, De SG, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 2014;9:e92153.
7. Oh DY, Barr IG, Mosse JA, Laurie KL. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol. 2008;46:2189–2194.
8. Isenberg HD. Clinical Microbiology Procedures Handbook, 1st edn. Washington, DC: American Society for Microbiology; 1992.
9. Hurt AC, Leang SK, Tiedemann K, et al. Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient. Influenza Other Respir Viruses 2013;7:904–908.
10. Hurt AC, Nor'e SS, McCaw JM, et al. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol 2010;84:9427–9438.
11. Murtaugh W, Mahaman L, Healey B, et al. Evaluation of three influenza neuraminidase inhibition assays for use in a public health laboratory setting during the 2011-2012 influenza season. Public Health Rep. 2013;128(Suppl 2):75–87.
12. Tamura D, Nguyen HT, Sleeman K, et al. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrob Agents Chemother. 2013;57:6141–6146.
13. Little K, Leang SK, Butler J, et al. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill. 2015;20:1–9.
14. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol. 2003;41:742–750.